title: New developments in the management of borderline resectable pancreatic cancers.
abstract: There remains great variability in the treatment for patients with borderline resectable pancreatic head cancers. Whether surgery should be attempted or neoadjuvant therapy consisting of chemoradiation or chemotherapy alone is at some debate. Each neoadjuvant regimen does show efficacy but there is no clear consensus which would be most beneficial. We will discuss three abstracts (#4043, #4057, #e15082) that were presented in the 2013 ASCO Annual Meeting that will discuss neoadjuvant therapies and how they are related to getting an R0 resection.
authors.affiliation: Tufts Medical Center. Boston, MA 02111, USA. mgoodman@tuftsmedicalcenter.org
authors.forename: Martin David
authors.initials: MD
authors.lastname: Goodman
authors.forename: Sarah
authors.initials: S
authors.lastname: McPartland
authors.forename: Kathryn
authors.initials: K
authors.lastname: Huber
authors.forename: Muhammad Wasif
authors.initials: MW
authors.lastname: Saif
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018395:CA-19-9 Antigen / Q000097:blood; D002208:Caproates / Q000008:administration & dosage; D059248:Chemoradiotherapy; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D000077143:Docetaxel; D006801:Humans; D020360:Neoadjuvant Therapy; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery*; D011237:Predictive Value of Tests; D011379:Prognosis; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D018395:CA-19-9 Antigen; D002208:Caproates; D043823:Taxoids; D000077143:Docetaxel; C111024:gemcabene